Benralizumab, approved by the EU for the treatment of eosinophilic granulomatosis with polyangiitis
Benralizumab, a drug developed by Astrazeneca, has obtained approval from the European Commission as an additional treatment for adult patients suffering from relapsed or refractory eosinophilic granulomatosis with polyangiitis (EGPA). EGPA is a rare immune-mediated vasculitis that can cause damage to several organs and, if not adequately treated, can be fatal for the patient. As … Read more